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From Scutellaria barbata to BZL101 in 
Cancer Patients: Phytochemistry, 
Pharmacology, and Clinical Evidence
Jiayu Gao1, Weiping Yin1, and Olivia Corcoran2
Abstract
Scutellaria barbata D.Don is a popular Chinese medicinal plant documented to treat cancer patients in traditional Chinese medicine 
(TCM). A botanical new investigational drug for breast cancer BZL101 (FDA IDN# 59521) was previously developed in the 
United States from the aqueous extract of the aerial parts from S. barbata. The early phase 1A and 1B clinical trials show its favor-
able toxicity profiles, good clinical tolerance, and promising efficacy for patients with metastatic breast cancer. To further evidence 
the phytopharmacology research, drug development, and anticancer use of this herb, a systematic literature review was performed 
herein on the phytochemistry, pharmacology, and specifically anticancer clinical evidence. A systematic review of the literature on 
phytochemical and pharmacological properties of the plant related to cancer treatment employed several web-based scientific da-
tabases including Wanfang (Chinese), Pubmed, Web of Science, and Elsevier. Key words included Scutellaria barbata, Ban Zhi Lian, 
cancer, and tumor. Based on critical quality criteria, only 8 out of 69 reports related to clinical studies of cancer patients in China. 
This review covered the available literature up to July 2019. The anticancer effects of S. barbata can be explained by the presence 
of various flavonoids and diterpenoids alkaloids. The underlying mechanisms are primarily summarized as cyclin/cyclin-dependent 
kinase (CDK)-modulated cell cycle arrest and mitochondria-mediated apoptotic death. The highly cancer-cell selective cytotoxicity 
and detoxifying effects of S. barbata contribute to a favorable clinical profile and enhanced quality of life for the cancer patient, 
thereby demanding further study as an adjuvant or alternative to conventional chemotherapy. The phytochemical and pharmaco-
logical studies reviewed strongly underpin a fundamental understanding of the anticancer activity of S. barbata and support ongoing 
clinical trials. The further safety verification and clinical trials are expected to progress S. barbata-based development to finally 
transform the traditional TCM herb S. barbata to the valuable anticancer drug.
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Scutellaria barbata D.Don (S. barbata), commonly known as Ban 
Zhi Lian in China and belong to the family Lamiaceae, is a pop-
ular medicinal plant (Figure 1) with a long history of  use in 
traditional Chinese medicine (TCM). The plant name was first 
documented in “Wai Ke Zheng Zong” by Shigong Chen in 
1617 ad.1 In China through the centuries, the whole herb of  S. 
barbata has been traditionally used as a source of  drugs for 
treating symptoms associated with carbuncle, scrofula, hae-
matemesis, epistaxis, ascites, traumatic injuries, and especially 
tumors (mainly lung, breast, and digestive system cancers).2,3 
Data from the Taiwan National Health Insurance Research 
Database report S. barbata as one of  the most common herbs 
used for the core treatment of  TCM prescriptions in breast 
cancer patients.4 According to bibliographic investigation using 
peer-reviewed articles in the Wanfang (Chinese literature), 
Pubmed, Web of  Science, and Elsevier database, scientific 
interest in the medicinal activities of  S. barbata rose signifi-
cantly during the 1990s mainly in the United States and East 
Asian countries especially China. The antitumor activity and 
the underlying mechanisms have been the most researched 
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aspect of  S. barbata. Moreover, phytochemistry studies have 
isolated and identified from S. barbata over a hundred metabo-
lites with medicinal value. Antibacterial activities, anti-oxidant, 
liver protective, and immune regulation functions were also 
characterized in many in vitro or in vivo models. One of  the 
most significant outcomes of  all this knowledge, which may yet 
translate to the clinical application of  S. barbata in cancer treat-
ment, is the development of  BZL101 for breast cancer patients 
beyond China.
BZL101 (FDA IDN# 59521) is an aqueous extract of  the 
aerial part of  S. barbata that shows a favorable toxicity profile 
and is well tolerated by patients, and demonstrates promising 
efficacy for metastatic breast cancer in phase I clinical trials.5,6 
Moreover, the further clinical development of  BZL101 has 
been solidly advanced by continued phytochemistry and mech-
anistic investigations following clinical trials in patients with 
advanced breast cancer. In in vitro studies, BZL101 has demon-
strated selective cytotoxicity to breast cancer cells over non-
transformed mammary epithelial cells.7,8 This cancer-specific 
killing might account for its favorable toxicity profile and good 
tolerance observed in early clinical trials when compared to 
chemotherapeutic agents such as cyclophosphamide, thiotepa, 
and 5-fluorouracil (5-FU). The mechanisms underlying anti-
cancer activities of  BZL101 were revealed as the mitochon-
dria-targeted inhibition of  metabolic pathways in a combined 
proteomic and metabolomic study.7,9,10 On treatment with S. 
barbata extract, the mitochondria of  tumor cells were shown to 
progressively respire high levels of  superoxide and perox-
ide-type reactive oxygen species (ROS). BZL101 thus inhibits 
oxidative phosphorylation and depletes mitochondrial reserve 
capacity depriving the abilities of  cancer cells to produce ATP 
followed by the inhibition of  glycolysis and then cell death.9 
Flavonoids, mainly scutellarein as well as carthamidin, were 
determined as active anticancer constituents of  BZL101 in a 
recent study. However, the maximal activity of  BZL101 
appears to need a combination of  compounds as the synergis-
tic effect is observed experimentally.11
Though the significant progress achieved during the devel-
opment of  BZL101, the development of  this S. barbata-based 
medicine was halted due to insufficient funding. To provide 
further evidence for the phytopharmacological research, drug 
development, and anticancer use of  this herb, we performed a 
systematic literature review on the phytochemistry, pharmacol-
ogy, and especially anticancer aspects of  S. barbata.
Materials and Methods
The authors searched a number of  electronic databases, includ-
ing Wanfang (Chinese), Pubmed, Web of  Science, and Elsevier 
up to July 30, 2019. The keywords for searching include 
Scutellaria barbata, Ban Zhi Lian, cancer, and tumor. These key-
words were searched individually and in combination. The 
titles and abstracts of  each of  the articles were assessed to 
delete duplication data. Searching was limited to articles only in 
the English or Chinese language. The articles with the contents 
unrelated to cancer were excluded. Patents, abstracts, case 
reports, and abstracts in symposia and congress were excluded 
due to insufficient information for evaluation and comparison 
with other studies. Review articles were also excluded as the 
data of  them were not original. Based on the above criteria, 69 
scientific articles were eligible for evaluation in this study.
No clinical reports were found in the selected English data-
bases, including Pubmed, Web of  Science, and Elsevier data-
base. The keywords (in Chinese) “Ban Zhi Lian” with 
“antitumor” and “anticancer” were used to retrieve peer-re-
viewed clinical reports in the Chinese Wanfang database. The 
criteria for selecting quality publications for clinical trials 
included only the reports that (1) clearly indicated the compo-
sition of  a formula, (2) daily dose of  each herbs, and (3) reports 
that employed the internationally accepted clinical criteria: 
Response Evaluation Criteria in Solid Tumors (RECIST)12 or 
WHO Response Evaluation Criteria13 or years’ survival rates to 
evaluate treating results is referred to here. Only 8 scientific 
articles passed the quality criteria on reporting clinical trials and 
were considered for clinical outcomes.
Phytochemical and Pharmacological Properties 
of  Scutellaria barbata
The bioactive secondary metabolites are the basic functional 
units of  medicinal plants. To date, multiple classes of  
Figure 1. Scutellaria barbata D.Don.
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phytochemicals, including flavonoids, essential oils, polysac-
charide, and terpenoid alkaloids, have been identified from 
S. barbata herb. Table  1 lists the identified phytochemicals 
accounting for pharmacological activities of  S. barbata.
Flavonoids, the class of  chemicals with anti-inflammatory, 
antioxidant, and anticancer properties, are the main bioactive 
components in S. barbata. Among them, scutellarin is reported 
as the highest content according to high performance liquid 
chromatography-ultraviolet (HPLC-UV) analysis.2 The pres-
ence of  scutellarin has been considered as the major effector 
of  the anticancer effects of  BZL101.11 On HCT-116 human 
colon cancer cells, scutellarin could reduce the cell viability and 
induce apoptosis by regulating p53 and Bcl-2/Bax expres-
sion.14 More recently, Scutellarein was found to induce Fas-
mediated extrinsic apoptosis by modulating the caspase-8, 
caspase-3, poly-ADP-ribose polymerase and death receptor 4, 
and G2/M cell cycle arrest by inhibiting the expression of  the 
proteins Cdc25C, CDK1, and Cyclin B1 in Hep3B hematoma 
cells.15 Besides scutellarin, carthamidin, apigenin, and luteolin 
(Figure 2) are the other antitumor flavonoids identified in S. 
barbata.11,16,17,43,44 Scutellarin and carthamidin induced DNA 
damage and oxidative cell death in breast cancer cells in vitro,11 
while luteolin exerted the inhibitory and apoptotic effects via 
caspase activation and extracellular signal-regulated kinase 
(ERK)/AKT suppression.17 Moreover, anti-angiogenic effects 
of  total flavonoids within S. barbata were confirmed45 and 
these may play a role in the matrix metalloproteinase (MMP)/
tissue inhibitor of  metalloproteinase related inhibition of  
tumor metastasis.46 Total flavonoids of  S. barbata could also 
induce the apoptosis of  human hepatocarcinoma MHCC97-H 
cells in a concentration-dependent manner via the mitochon-
drial pathway. The 48-hour treatment led to the significant 
upregulated expression of  apoptotic proteins including Smac, 
Table 1. Active Compounds Isolated From Scutellaria barbata.
Chemical 
classification Phytochemicals Pharmacological activity References
Flavonoid Scutellarin Anticancer (breast cancer cells MDAMB231, hepatoma 
cells Hep3B, colon cancer cells HCT-116)
11,14,15
Carthamidin
Apigenin Anticancer and antimicrobial 16
Luteolin 16,17
Essential oil Hexahydrofarnesylacetone Antimicrobial (myometrium and leiomyomal cells; Lewis 
lung carcinoma cells)
18
3,7,11,15-Tetramethyl-2-hexadecen-1-ol
Menthol
1-Octen-3-ol
Diterpenoid 
alkaloid
Scutebarbatines A-L, X Anticancer (HONE-1 nasopharyngeal, KB oral 
epidermoid carcinoma, A549 lung cancer, HT29 
colorectal carcinoma, LoVo colon cancer, LNCaP 
prostate cancer, SK-MEL-2 melanoma, MCF-7 breast 
cancer, SCG7901 gastric cancer, HL-60 leukemia, 
SMMC-7721 hepatoma cancer and HCT-116 colon 
cancer cells)
19-25
6,7-Di-O-nicotinoylscutebarbatine
G
21,25
6-O-Nicotinoyl-7-O-acetylscutebarbatine G
7-O-NicotinoylscutebarbatineH
Scutehenanine H 26
6-(2,3-Epoxy-2-isopropyl-n-propoxyl)barbatin C
Barbatellarines B 27
Barbatins A, C 20,24
Barbatins B-H 20,24,28
Scutelinquanines A-D 29,30
Scutebatas A-E, G, H, L-N, P-Q, C1 24,31-34
Scutehenanines A-D 35
6-O-Acetyiscutehenanine A
6-O-(2-Carbonyl-3-methylbutanoyl)scutehenanine 
A
Scutebarbatines M-O 36,37
6-Acetoxybarbatin C 30
6-O-Nicotinoylscutebarbatine G 36
Scutebarbalactone VN 38
Scutebarbatolides A, B 39
Scubatines F 40
Polysaccharide SBPW3, SPS2p Anitcancer (colon cancer) 41,42
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apoptotic protease activating factor-1, cytochrome c, caspase-9, 
and caspase-3.47
As terminal stage cancer patients often suffer serious micro-
bial infection, the presence of  flavonoids also contributes to 
the antimicrobial activity of  S. barbata. Luteolin and apigenin 
were reported in vitro to be selectively active against 
Staphylococcus aureus, including both methicillin-resistant 
(MRSA) and -sensitive strains.48 Essential oils are another class 
of  components that exhibit antimicrobial activity in S. barbata. 
A broad antimicrobial spectrum is observed but with stronger 
effects on gram-positive bacteria (including MRSA) than 
gram-negative bacteria or yeasts.18 The antibacterial activities 
may arise from the main oil constituents such as hexahydro-
farnesyl acetone (11.0%), 3,7,11,15-tetramethyl-2-hexade-
cen-1-ol (7.8%), menthol (7.7%), and 1-octen-3-ol (7.1%),18 
whose effects had been reported elsewhere.49-51
Polysaccharides isolated from S. barbata (PSB) could inhibit 
the proliferation of  human lung cancer 95-D cell line with IC50 
at 35.2 µg/mL. In vivo, PSB inhibited tumor growth in the 
95-D subcutaneous xenograft model in a dose-dependent 
manner. The treatment of  once-daily intraperitoneal injection 
(100 mg/kg) for 3 weeks was able to inhibit 42.72% tumor 
growth.52 Li et al also isolated a water-soluble polysaccharide, 
SBPW3, composed of  rhamnose, arabinose, xylose, mannose, 
glucose, and galactose. SBPW3 was found to effectively sup-
press transforming growth factor-beta (TGF-β) 1-induced 
migration and invasion by regulating the expression of  epithe-
lial and mesenchymal markers through blocking the Smad2/3 
signaling pathway in colon cancer cells. It could prevent cancer 
metastasis in animal model in vivo as well.41 SPS2p, another 
water-soluble polysaccharide isolated from S. barbata, was also 
reported to promote the apoptosis in HT29 colon cancer cells 
through regulating the phosphoinositide 3-kinase (PI3K)/
AKT pathway.42 This demonstrated the potential antitumor 
activity for polysaccharides of  S. barbata.
Diterpenoid alkaloids are the most widely reported com-
pounds from S. barbata with cytotoxic activities tested on 
cancer cell lines. Their in vitro cytotoxicities have been identi-
fied on at least one of  the following cancer cell lines including 
HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, 
HT29 colorectal carcinoma,19-22,29,30,35-37,39,53,54 HL-60 leuke-
mia,27,31,32,40 SK-BR-3 breast adenocarcinoma,32 K562 erythro-
myeloblastoid leukemia, HepG2 and SMMC-7721 
hepatocellular carcinoma,3,23,24,39 A549 lung adenocarci-
noma,3,23 LNCaP prostate cancer, SK-MEL-2 melanoma,39 
MCF-7 breast adenocarcinoma,24,37,39 SGC7901 gastric can-
cer,33 LoVo,24 HCT-116,24,28 and SW480 colon adenocarci-
noma cells32 with IC50 values ranging from 2.0 to over 100 µM. 
The 6-(2,3-epoxy-2-isopropyl-n-propoxyl) barbatin C 
(Figure 3) was the most cytotoxic neo-clerodane diterpenoid 
reported so far with IC50 as low as 2.0 µM to KB oral epider-
moid cancer cells.26
Rationale for the Use of  Scutellaria barbata 
to Treat Cancer Patients
Though still at an early stage of  clinical validation the existing 
evidence already defines the anticancer potential of  S. barbata, 
this conclusion is supported mainly by evidence from (1) the 
traditional use and therapeutic evaluation; (2) pharmacology 
data established by both in vitro and in vivo models; and (3) 
ongoing clinical trials.
Clinical Uses of  Scutellaria barbata Formulae in Cancer 
Treatment Across China
The herbal formulae, usually decoctions comprising dozens of  
medicinal plants of  differing amounts, are the typical dosage 
Figure 2. Antitumor flavonoids identified from Scutellaria barbata.
Figure 3. 6-(2,3-Epoxy-2-isopropyl-n-propoxyl)barbatin C.
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form of  TCM. Numerous herbal formulas of  TCM have been 
empirically developed over the centuries and claim to treat can-
cer-like symptoms in Chinese hospitals and private clinics. As 
one of  the most popular anticancer herbs in TCM, S. barbata is 
widely used in many such formulae. However, the medicinal 
value of  such formulas is extremely hard to evaluate due to the 
lack of  authoritative clinical reports. In this review, we evalu-
ated Chinese language scientific reports concerning the clinical 
research on anticancer herbs.
As shown in Table 2, out of  a total of  69 eligible papers 
evaluated through the systematic review, only 8 clinical reports 
of  none of  the random control test (RCT) double blind studies 
in Chinese on S. barbata-containing herbal formulae complied 
with our quality screening criteria.55-62 In all 8 clinical studies, 
herbal metabolites were delivered as decoctions to the target 
location by oral administration. The weight of  S. barbata used 
to prepare the decoction is between 10 and 30 g/day. According 
to the Chinese Pharmacopeia, the quality standard for S. bar-
bata must contain over 0.20% scutellarin.2 The daily dosage of  
scutellarin, claimed to be the major anticancer constituent of  S. 
barbata,11 is thus estimated in the range 20 to 60 mg within 
those herbal formulae. However, the determination of  actual 
concentration of  scutellarin is an impossible task due to the 
variation of  drug preparation and complex chemical composi-
tion within decoctions. The cancer patients are typically 
instructed by TCM doctors to prepare the decoction at home 
by boiling herbal mixtures in water (once or twice to produce 
300-400 mL). The decoctions are then self-administered 2 to 3 
times daily. Clearly, the multiple factors, such as preboiling pro-
cedures (washing and grinding), boiling time, herbal quality, 
starting liquid volume, and chemical reactions during boiling, 
can influence the composition and concentration of  active 
compounds in the resulting beverage. To better understand the 
phytochemical basis underlying the application of  such herbal 
formulae, chemical fingerprinting for drug metabolites in the 
decoction formulations and in vivo biological fluid sampling 
(serum or urine from patients) is strongly suggested for future 
clinical experiments.
Moreover, the therapeutic evaluations of  antitumor effects 
in cancer patients are usually made over a 2-month treatment. 
In 8 clinical trials reported here, herbal formulae were used 
either alone or as the adjuvant to the conventional chemo/
radiotherapy. The complete response (CR) and partial response 
(PR) used as indicators of  tumor size reduction were used to 
evaluate the short-term effects and the years’ survival rate rep-
resented the long-term outcome. As shown in Table 2, the herb 
plus treatment demonstrated statistically significant improve-
ment on either or both of  the evaluating parameters compared 
to the parallel chemo/radiotherapy. The trials without parallel 
treatment also partly showed therapeutic effects in cancer 
therapy.
Taken together, despite issues concerning the quality of  8 
identified TCM clinical reports, including that of  herbal 
authentication, no provided chemical profiles (by HPLC-UV 
or liquid chromatography-mass spectrometer [LC-MS for 
example) and limited patient numbers (all less than 100 
cases), the anticancer potential of  reported formulae includ-
ing S. barbata is claimed. The positive treatment outcomes as 
judged by objective parameters (CR, PR, or year survival 
rate) has constructed the basis for further developing the 
anticancer use of  S. barbata in both the laboratory and the 
clinic.
In Vitro Effects of  Scutellaria barbata on Human Cell 
Lines
According to reports published since 2003, the S. barbata extract 
has been identified as a growth inhibitor on a broad range of  
cancer cells in vitro (Table 3).63–71 Aqueous extract of  S. barbata 
showed inhibitory effects for the growth of  11 ovarian, 2 breast 
cancer cell lines, leukemia cells, hepatoma cells as well as leiomy-
omal cells through inducing mitochondria-mediated apoptosis 
and arresting the cell cycle at G1 stages.
63-67 This inhibition is 
commonly achieved through regulating the CDK/cyclin cascade 
and apoptotic proteins.64-67 Specially, methanol extracts of  S. bar-
bata were reported in inducing the G2/M phase arrest of  lung 
cancer cell CL1-5 through reducing the levels of  Cdc25C, cyclin 
A, cyclin B1, and Cdc2.71 The actively proliferating cells were 
more sensitive to the treatment, which suggests the potential 
selectivity of  S. barbata on cancers over normal tissues. This is 
consistent with fewer side-effects of  BZL101 observed in clinical 
trials. Moreover, sensitivities of  treatment varied among different 
cell lines, leading to different survival rates of  cancer cells under 
Bcl-2 transfection.63 The ethanol extract of  S. barbata could sig-
nificantly suppress the activation of  STAT3, ERK, and p38 sig-
nalings through regulation of  multiple critical genes expression 
such as Bcl-2, Bax, Cyclin D1, CDK4, caspase 3/9, and p21 in 
colon and ovarian cancer cells.63–73 The chloroform fraction of  S. 
barbata increased the ratio of  the pro-apoptotic Bax/Bcl-2, and 
decreased the expression of  the pro-proliferative cyclin D1 and 
cyclin-dependent kinase 4 and tumor suppressor miR-34a in 
human colon cancer cells.74,75 Compared to the other organic sol-
vent fractions, the methylene chloride fraction was the most cyto-
toxic demonstrating concentration-dependent effects with IC50 
as low as 10 µg/mL on leukemia cells. The mechanism featured 
as typically mitochondria-mediated apoptotic progress including 
caspases activation and bcl proteins modulation.68 Scutellaria bar-
bata was also characterized as an effective regulator for AKT/
protein kinase B (PKB), whose disruption frequently occurred in 
numerous types of  human cancers. This regulation was believed 
to be the critical part of  the S. barbata’s antitumor and anti-angio-
genic functions.70 The ethanol extract of  S. barbata could effec-
tively promote the growth inhibition and apoptosis of  human 
colon carcinoma cells HT-29 via modulation of  the interleukin 
(IL)-6/STAT3 signaling pathway and its target genes.76 The 
apoptosis induced by ethanol extract of  S. barbata was also found 
to be mediated through mitochondria- , caspase- and Mitogen-
Activated Protein Kinase (MAPK) dependent pathways in MKN-
45 gastric adenocarcinoma cells. It enhanced ROS generation and 
increased the chemosensitivity of  MKN-45 cells.77 In addition, 
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ethanol extract of  S. barbata decreased the expression of  MMP-1, 
MMP-2, MMP-3/10, MMP-9, and MMP-13, and proteins in the 
PI3K/AKT and TGF-β/Smad pathways, thus inhibiting cell 
metastasis of  colorectal cancer.78 Importantly, the anticancer 
effect of  ethanol extract of  S. barbata was presented in a 
5-FU-resistant colorectal cancer cell line HCT-8/5-FU by regu-
lating PI3K/AKT pathway. It indicated the potentials of  S. bar-
bata aganist chemoresistance, which was a major obstacle in 
clinical treatment of  cancers.79 In a global genomics screening 
study using cDNA microarray analysis, the S. barbata-induced 
apoptotic death of  cancer cells was determined as multiple genes 
involved in mechanisms including control of  DNA damage, cell 
cycle, nucleic acid binding, and protein phosphorylation.69 
However, to the best of  our knowledge, further details on the 
anticancer mechanistic network of  S. barbata has not been 
reported in the literature.
Taken together, the in vitro studies reported to date have indi-
cated the cytotoxicity of  S. barbata extracts on most of  the cancer 
cell lines tested. The anticancer mechanisms were primarily iden-
tified as antiproliferative growth arrest and then mitochon-
dria-mediated apoptotic death. However, the detailed molecular 
mechanisms are still far from clear at both proteomic and 
genomic levels and thus remain an ongoing challenge. The level 
of  such understanding would expand our knowledge regarding 
Table 3. The Anticancer Activities of Scutellaria barbata Extracts.
Extract types Cancer types Cell lines IC50 (μg/mL)Mechanisms References
Water Ovarian SKOV3 - G1 arrest; apoptosis
63
A2780 PARENT
A2780 CP70
A2780 V
A2780 MP53
HA8
HEY
HEY C2
OVCAR-3
CAOV3
OCC
Breast SKBR3
MCF7
Leiomyoma LM-1/2 - G1 arrest; apoptosis; caspase-3 activity↑; cyto-c release; 
α-smooth muscle actin↑; calponin h1↑; p27↑
64,65
Leukemia HL-60 - G1 arrest; apoptosis;cyclin A↓; cyclin D↓; cyclin E↓; 
CDK2↓; CDK4↓; CDK6↓; p21↑; pRb↓
66
Hepatoma H22 - G1 arrest; apoptosis;mitochondrialtransmembrane 
potential↓; caspase-3 activation; cyto-c release
67
Methylene chloride Leukemia U937 10 Apoptosis; caspase-3/9 activation; Bax/Bcl-2↑;cyto-c 
release
68
Ethanol Lung A549 210 Apoptosis; DNA damage; cell cycle control; nucleic acid 
binding; protein phosphorylation
69
Colon HT-29 - Apoptosis; caspase-3/9 activation; cyclin 
D1↓;CDK4↓;Bcl-2↓
76
HCT-8/5-FU - Cyclin D1↓; Bcl-2↓; ABCG2↓; p21↑; Bax↑; suppression 
of  the PI3K/AKT pathway
79
Gastric MKN-45 105.6 Apoptosis; caspase-3/9 activation; MAPK dependent; 
ROS generation
77
Ovarian A2780 - Apoptosis; caspase-3/9 activation; Bcl-2↓; MMP-2/9↓ 72
Colorectal HCT-8 - MMPs↓; PI3K/AKT, and TGF-beta/Smad pathways 
suppression
78
Methanol Colorectal LoVo - Phosphorylated AKT↓ 70
Lung CL1-5 - G2/M arrest; Cdc25C↓; cyclin A↓; cyclin B1↓; 
Cdc2↓; apoptosis, caspase 7↑; caspase 3↑; PARP↑; 
caspase 4↑; Bcl-2↓; Bcl-xs↑; FasL↑; SIRT1↓; 
phosphorylation of  P38 ↑
71
Chloroform Colon HCT-8 - Apoptosis; miR-34a↑; Bcl-2↓;Notchl/2↓; Jagged1↓ 74
MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinase; PI3K, phosphoinositide 3-kinase.
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the anticancer properties of  natural products and further aid the 
development of  anticancer drug from those sources.
In Vivo Antitumor Effects of  Scutellaria barbata in 
Animal Models
On the basis of  the above in vitro studies, the antitumor 
effects of  S. barbata or its fractions were gradually reported 
in recent years. The polysaccharide fraction of  S. barbata 
inhibited by up to 34.35% growth of  tumors in the hepato-
carcinoma H22-bearing mice80,81 with similar inhibition also 
observed in S180 sarcoma-bearing mice.82 Meanwhile, 
immune defences of  experimental animals were strength-
ened, as characterized by increased weight of  immune 
organs, promoted serum IL-2 levels, and improved function 
of  monocyte-macrophages.80,82 Similarly, the tumor growth 
of  hepatoma H22-bearing mice was also significantly con-
trolled by crude extracts of  S. barbata. It could increase the 
efficacy of  spleen NK cells, downregulate the amount of  
Treg cells and Th17 cells in tumor tissue, and decrease serum 
IL-10, TGFγ, and IL-17A levels whereas increase IL-2 and 
IFNγ levels.83 Without loss of  body weight (a key indicator 
for side-effects), the size of  colorectal tumor and angiogen-
esis were significantly reduced in S. barbata-treated xenograft 
mice.73,84 The blockage of  the Sonic Hedgehog and the 
Wnt/beta-catenin pathway was then involved in the anti-an-
giogenic activity of  S. barbata through suppressed expression 
of  key mediators such as sonic hedgehog, patched-1, β-cat-
enin, c-Myc, surviving, smoothened, and the glioma-associ-
ated oncogene homolog 1.84,85 Moreover, Chen et al recently 
reported that the methanol extracts of  S. barbata suppress 
tumor growth in mouse CL1-5 (lung cancer cell) xenograft 
models through apoptosis, autophagy, anti-angiogenesis, and 
antiproliferation, which were similar to those of  S. barba-
ta-treated CL1-5 cells in vitro.71 Besides inhibiting the tumor 
growth, S. barbata also presented protective effects against 
tumorigenesis. In diethylnitrosamine-stimulated animal 
models, the liver tumorigenesis was significantly inhibited 
after exposure to S. barbata extracts, featuring a reduced 
number of  tumor nodules, elevated activities of  serum ala-
nine aminotransferase and aspartate aminotransferase, and 
inhibited levels of  tumor markers including gamma-glutamyl 
transferase, glutathione-S-transferase, and alpha-l-fucosi-
dase.86 As a currently used adjuvant of  conventional chemo-
therapy, S. barbata greatly synergized the antitumor effect of  
low dose 5-FU (2 µg/mL or 8 mg/kg) both in vitro (Bel-
7402 and HCT-8 cell lines) and in vivo (H22 transplanted 
hepatocarcinoma Kunming mice). Apoptotic death of  can-
cer cells was induced under such combined treatment 
through the activation of  caspase-3 and the modulation of  
apoptotic proteins including p53, Bcl-2, Bax, and bid.87 
Moreover, S. barbata polysaccharides were recently found to 
inhibit the growth of  Calu-3 xenograft tumors through 
blocking the HER2 pathway and angiogenesis.88
In summary, the antitumor effects of  S. barbata have been 
confirmed in several in vivo models. The data obtained from 
these in vivo experiments are greatly in agreement with S. bar-
bata traditional uses and in vitro activity. These and in vivo pre-
clinical animal experiments also offer the foundations for 
proposed BZL101 clinical trials.
Phase 1A and 1B Clinical Trials
As described above, the safety and efficacy of  BZL101 (the 
drug developed from crude aqueous extracts of  S. barbata) 
for treating metastatic breast cancers has been assessed in 
early phases of  clinical trials in the United States. In a phase 
1A trial, the crude herb S. barbata was extracted in hot water 
and the crude liquids produced were orally administered to 
patients. According to Common Toxicity Criteria,89 no grade 
III or IV adverse events occurred during the BZL101 treat-
ment. The grade I and II side events related to BLZ101 were 
mainly gastrointestinal symptoms including nausea (48%), 
vomiting (10%), gagging (5%) as well as diarrhea, constipa-
tion, bloating, gas, and abdominal cramping.6 These effects 
were thought to be caused by the bitterness and insoluble 
plant roughage from unprocessed herbal materials in the 
study. In the subsequent phase 1B trial, the reformulation of  
BLZ101 using sweeteners and taste-enhancing excipients 
significantly improved the patient’s acceptance and achieved 
excellent tolerability with a median compliance of  92%. 
Compared to the conventional chemotherapeutic drugs 
capecitabine and lapatinib, BZL101 (maximum at 40 g daily) 
demonstrated more favorable toxicological profiles and thus 
represents a clear advancement in options for patients with 
metastatic breast cancers.5
In both the phase 1A and 1B trials, treatment with 
BZL101 shows early indications of  biological antitumor 
activity and a potential to delay disease progression. 
According to the Response Evaluation Criteria in Solid 
Tumors (RECIST),12 4 out of  16 patients enrolled in trial 1A 
have stable disease (SD) for over 90 days and 3 had SD for 
over 180 days. Moreover, 5 patients demonstrated a minimal 
response with one having 1 mm in tumor size reduction.6 In 
the further 1B trial with patients suffering metastatic breast 
cancers who had already undergone surgery, chemotherapy 
or radiotherapy before the trial, 5 of  14 experienced long 
periods of  SD and 3 were classified as SD for over 120 days. 
One patient was treated with BZL101 for 449 days and 
remained stable for over 700 days.5
In summary, the recent phase 1 clinical trials demon-
strated that BZL101, especially with the improved organo-
leptic formula, is safe, well tolerated with beneficial 
therapeutic activities for patients with metastatic breast can-
cers. Although the development of  BZL101 was halted due 
to funding problems, the further development of  the S. bar-
bata-based anticancer drug formula and advanced phase clin-
ical trials remains promising.
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Safety and Drug Interactions
Though the systemic toxicity and safety evaluations are still 
inadequate for drug development, the lower toxicity of  S. 
barbata in cancer treatment was evidenced in the early phase 
clinical trials.5,6 In preclinical animal research, S. barbata has 
been determined as an effective synergistic and toxicity-re-
ducing agent for chemotherapy in both in vitro and in vivo 
cancer models.87,90-92 In the hepatoma H22 tumor-bearing 
mice undergoing 5-FU treatment, the co-administration of  
S. barbata could significantly enhance the tumor inhibition 
rate, reduce toxic effects including abdominal distention, 
listlessness, and emaciation, prolong the survival time and 
upregulate immune function.90 Moreover, S. barbata demon-
strated protective and recovery effects against cisplatin-in-
duced nephrotoxicity in mice. Scutellaria barbata pretreatment 
could ameliorate renal dysfunction as indicated by serum 
creatinine and blood urea nitrogen level, as well as reduce 
pro-inflammatory cytokines secretion and tubular injury in 
cisplatin-treated mice.91,92 The cisplatin-induced damage 
could be strongly recovered by S. barbata on Human 
Embryonic Kidney 293 cells.92 However, the toxicology and 
co-efficacy activities of  S. barbata need further assessment 
along with the commonly used chemo-drugs and experimen-
tal models in preclinical tests and then clinical trials, which 
would lead to its application as an adjuvant drug for cancer 
treatment.
Conclusion
As one of  the first botanical investigational new drugs approved 
by FDA, BZL101 (S. barbata) has been of  increasing interest in 
recent years. The numerous phytochemical and pharmacological 
studies reviewed in this article help to validate the anticancer 
potential of  S. barbata and strongly support ongoing and any fur-
ther clinical trials proposed. Its cytotoxicity effects can be 
explained by the presence of  various flavonoids and diterpenoid 
alkaloids. The mechanisms underlying anticancer effects could be 
summarized as cyclin/CDK-modulated cell cycle arrest and 
mitochondria-medicated apoptotic death. The highly selective 
cytotoxicity and detoxifying effects of  S. barbata, which denote a 
favorable clinical profile, may receive more interest as an adjuvant 
medicine to conventional chemotherapy.
Based on the review of  current research, there is a need to 
further detail the anticancer mechanisms of  S. barbata at both 
genomic and proteomic levels. Efforts should also be made to 
determine the identity, pharmacokinetics, bioavailability, and 
physiological pathways of  functionally anticancer constituents in 
S. barbata. Further safety verification and clinical trials are 
expected to progress S. barbata-based anticancer drug develop-
ment and finally succeed in transforming S. barbata the traditional 
Chinese medicine to a new drug for women suffering from breast 
cancer.
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